menu
    • menu
    [{"orgOrder":0,"company":"Pharos iBio","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PHI-101","moa":"Chk2","graph1":"Oncology","graph2":"Phase I","graph3":"Pharos iBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharos iBio \/ Pharos iBio","highestDevelopmentStatusID":"6","companyTruncated":"Pharos iBio \/ Pharos iBio"},{"orgOrder":0,"company":"Pharos iBio","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PHI-101","moa":"Chk2","graph1":"Oncology","graph2":"Phase I","graph3":"Pharos iBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharos iBio \/ Pharos iBio","highestDevelopmentStatusID":"6","companyTruncated":"Pharos iBio \/ Pharos iBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharos iBio

    Menu

    Pharos iBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharos iBio

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed

                            Pharos iBio

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of...

                            Details : PHI-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 13, 2021

                            Lead Product(s) : PHI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharos iBio

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed

                            Pharos iBio

                            South Korea arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PHI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

                            Details : PHI-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : PHI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth